Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa

Rachna Rastogi, Ryan S. Teller, Pedro M M Mesquita, Betsy Herold, Patrick F. Kiser

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Vaginal pre-exposure prophylaxis has focused heavily on gel formulations. Low adherence linked with frequent dosing and short therapeutic duration has emerged as the major reason for inconsistent efficacy outcomes with gels in clinical trials. Osmotic pumps can achieve versatile drug release profiles however, have not been explored for vaginal delivery. In this report, we describe an osmotic pump tablet (OPT) that can deliver antiretrovirals for several days. We also describe configuring the OPT for pH sensitive delivery where the drug delivery system consistently delivers an antiretroviral at vaginal pH and then gives a burst release triggered by a coitally associated pH increase. We have investigated the vaginal OPT for multiple day delivery of a potent antiretroviral, IQP-0528 in a sheep model. To effectively register spatial drug distribution we also engineered a tool to precisely collect multiple vaginal fluid samples. In a 10-day duration post single application, high micromolar mucosal levels were obtained with peak concentration more than 6 logs higher than the EC50 of IQP-0528. Overall, our results show successful implementation of the osmotic pump technology for vaginal antiretroviral delivery.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalAntiviral Research
Volume100
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Tablets
Mucous Membrane
Gels
Drug Delivery Systems
Sheep
Clinical Trials
Technology
Pharmaceutical Preparations
IQP-0528
Therapeutics
Drug Liberation
Pre-Exposure Prophylaxis

Keywords

  • Antiretroviral
  • Multiswab device
  • Osmotic pump
  • Spatial drug distribution
  • Vaginal

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. / Rastogi, Rachna; Teller, Ryan S.; Mesquita, Pedro M M; Herold, Betsy; Kiser, Patrick F.

In: Antiviral Research, Vol. 100, No. 1, 2013, p. 255-258.

Research output: Contribution to journalArticle

Rastogi, Rachna ; Teller, Ryan S. ; Mesquita, Pedro M M ; Herold, Betsy ; Kiser, Patrick F. / Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. In: Antiviral Research. 2013 ; Vol. 100, No. 1. pp. 255-258.
@article{983c473f5e2a4a92963a413f7444cb58,
title = "Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa",
abstract = "Vaginal pre-exposure prophylaxis has focused heavily on gel formulations. Low adherence linked with frequent dosing and short therapeutic duration has emerged as the major reason for inconsistent efficacy outcomes with gels in clinical trials. Osmotic pumps can achieve versatile drug release profiles however, have not been explored for vaginal delivery. In this report, we describe an osmotic pump tablet (OPT) that can deliver antiretrovirals for several days. We also describe configuring the OPT for pH sensitive delivery where the drug delivery system consistently delivers an antiretroviral at vaginal pH and then gives a burst release triggered by a coitally associated pH increase. We have investigated the vaginal OPT for multiple day delivery of a potent antiretroviral, IQP-0528 in a sheep model. To effectively register spatial drug distribution we also engineered a tool to precisely collect multiple vaginal fluid samples. In a 10-day duration post single application, high micromolar mucosal levels were obtained with peak concentration more than 6 logs higher than the EC50 of IQP-0528. Overall, our results show successful implementation of the osmotic pump technology for vaginal antiretroviral delivery.",
keywords = "Antiretroviral, Multiswab device, Osmotic pump, Spatial drug distribution, Vaginal",
author = "Rachna Rastogi and Teller, {Ryan S.} and Mesquita, {Pedro M M} and Betsy Herold and Kiser, {Patrick F.}",
year = "2013",
doi = "10.1016/j.antiviral.2013.08.007",
language = "English (US)",
volume = "100",
pages = "255--258",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa

AU - Rastogi, Rachna

AU - Teller, Ryan S.

AU - Mesquita, Pedro M M

AU - Herold, Betsy

AU - Kiser, Patrick F.

PY - 2013

Y1 - 2013

N2 - Vaginal pre-exposure prophylaxis has focused heavily on gel formulations. Low adherence linked with frequent dosing and short therapeutic duration has emerged as the major reason for inconsistent efficacy outcomes with gels in clinical trials. Osmotic pumps can achieve versatile drug release profiles however, have not been explored for vaginal delivery. In this report, we describe an osmotic pump tablet (OPT) that can deliver antiretrovirals for several days. We also describe configuring the OPT for pH sensitive delivery where the drug delivery system consistently delivers an antiretroviral at vaginal pH and then gives a burst release triggered by a coitally associated pH increase. We have investigated the vaginal OPT for multiple day delivery of a potent antiretroviral, IQP-0528 in a sheep model. To effectively register spatial drug distribution we also engineered a tool to precisely collect multiple vaginal fluid samples. In a 10-day duration post single application, high micromolar mucosal levels were obtained with peak concentration more than 6 logs higher than the EC50 of IQP-0528. Overall, our results show successful implementation of the osmotic pump technology for vaginal antiretroviral delivery.

AB - Vaginal pre-exposure prophylaxis has focused heavily on gel formulations. Low adherence linked with frequent dosing and short therapeutic duration has emerged as the major reason for inconsistent efficacy outcomes with gels in clinical trials. Osmotic pumps can achieve versatile drug release profiles however, have not been explored for vaginal delivery. In this report, we describe an osmotic pump tablet (OPT) that can deliver antiretrovirals for several days. We also describe configuring the OPT for pH sensitive delivery where the drug delivery system consistently delivers an antiretroviral at vaginal pH and then gives a burst release triggered by a coitally associated pH increase. We have investigated the vaginal OPT for multiple day delivery of a potent antiretroviral, IQP-0528 in a sheep model. To effectively register spatial drug distribution we also engineered a tool to precisely collect multiple vaginal fluid samples. In a 10-day duration post single application, high micromolar mucosal levels were obtained with peak concentration more than 6 logs higher than the EC50 of IQP-0528. Overall, our results show successful implementation of the osmotic pump technology for vaginal antiretroviral delivery.

KW - Antiretroviral

KW - Multiswab device

KW - Osmotic pump

KW - Spatial drug distribution

KW - Vaginal

UR - http://www.scopus.com/inward/record.url?scp=84883897871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883897871&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2013.08.007

DO - 10.1016/j.antiviral.2013.08.007

M3 - Article

VL - 100

SP - 255

EP - 258

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -